During the last session, Evaxion Biotech A/S ADR (NASDAQ:EVAX)’s traded shares were 3.6 million, with the beta value of the company hitting -0.30. At the end of the trading day, the stock’s price was $3.64, reflecting an intraday gain of 52.94% or $1.26. The 52-week high for the EVAX share is $68.05, that puts it down -1769.51 from that peak though still a striking 34.62% gain since the share price plummeted to a 52-week low of $2.38. The company’s market capitalization is $3.93M, and the average intraday trading volume over the past 10 days was 0.13 million shares, and the average trade volume was 90.45K shares over the past three months.
Evaxion Biotech A/S ADR (EVAX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. EVAX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
Evaxion Biotech A/S ADR (EVAX) registered a 52.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 52.94% in intraday trading to $3.64, hitting a weekly high. The stock’s 5-day price performance is 10.64%, and it has moved by -18.21% in 30 days. Based on these gigs, the overall price performance for the year is -80.12%. The short interest in Evaxion Biotech A/S ADR (NASDAQ:EVAX) is 0.2 million shares and it means that shorts have 1.07 day(s) to cover.
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Statistics show that Evaxion Biotech A/S ADR has outperformed its competitors in share price, compared to the industry in which it operates. Evaxion Biotech A/S ADR (EVAX) shares have gone down -73.48% during the last six months, with a year-to-date growth rate more than the industry average at 89.38% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -18.88%. While earnings are projected to return 89.88% in 2025.
EVAX Dividends
Evaxion Biotech A/S ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Data provided on Nov 30, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 670.0 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $2438.0 market value.
